Clinical nutrition, body composition and oncology: A critical literature review of the synergies

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 1, 2012, Pages 37-46

  Jacquelin Ravel, Nathalie ^a,b   Pichard, Claude ^b  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Body composition; Body surface area; Cancer; Chemotoxicity; Nutrition

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CYTOTOXIC AGENT; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; PLACEBO; SORAFENIB;

ADVANCED CANCER; AGING; BODY COMPOSITION; BODY MASS; BODY SURFACE; BREAST METASTASIS; CACHEXIA; CANCER PATIENT; CANCER PROGNOSIS; COLON CANCER; DRUG DOSE REDUCTION; ENERGY EXPENDITURE; HUMAN; KIDNEY CARCINOMA; LEAN BODY WEIGHT; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MUSCLE ATROPHY; MUSCLE STRENGTH; NEUTROPENIA; NUTRITION; NUTRITIONAL ASSESSMENT; NUTRITIONAL SUPPORT; OBESITY; ONCOLOGY; OVERALL SURVIVAL; PARENTERAL NUTRITION; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; SKELETAL MUSCLE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

BODY COMPOSITION; CACHEXIA; HUMANS; NEOPLASMS; NUTRITIONAL SUPPORT;

EID: 84866502203     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.02.001     Document Type: Review

References (57)

1. Bachmann J., Heiligensetzer M., Krakowski-Roosen H., Büchler M.W., Friess H., Martignoni M.E. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008, 12(7):1193-1201.
2. Tan B.H., Fearon K.C. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008, 11(4):400-407.
3. Fearon K., Strasser F., Anker S.D., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011, 12(5):489-495.
4. Fearon K.C., Voss A.C., Hustead D.S. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006, 83(6):1345-1350.
5. Skipworth R.J., Stewart C.G., Dejong C.H., Preston T., Fearon K.C. Pathophysiology of cancer cachexia: much more than host-tumour interaction?. Clin Nutr 2007, 26(6):667-676.
6. Evans W.J., Morley J.E., Argilés J., et al. Cachexia: a new definition. Clin Nutr 2008, 27(6):793-799.
7. Stephens N.A., Skipworth R.J., Macdonald A.J., Greig C.A., Ross J.A., Fearon K.C. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J Cachexia Sarcopenia Muscle 2011, 2(2):111-117.
8. Singer P., Berger M.M., Van den Berghe G., et al. ESPEN guidelines on parenteral nutrition: intensive care. Clin Nutr 2009, 28(4):387-400.
9. Janssen I., Heymsfield S.B., Wang Z.M., Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol 2000, 89(1):81-88.
10. Illner K., Brinkmann G., Heller M., Bosy-Westphal A., Müller M.J. Metabolically active components of fat free mass and resting energy expenditure in nonobese adults. Am J Physiol Endocrinol Metab 2000, 278(2):E308-E315.
11. Gullett N., Rossi P., Kucuk O., Johnstone P.A. Cancer-induced cachexia: a guide for the oncologist. J Soc Integr Oncol 2009, 7(4):155-169.
12. Jebb S.A., Osborne R.J., Dixon A.K., Bleenhen N.M., Elia M. Measurements of resting energy expenditure and body composition before and after treatment of small cell lung cancer. Ann Oncol 1994, 5(10):915-919.
13. Lieffers J.R., Mourtzakis M., Hall K.D., McCargar L.J., Prado C.M., Bracos V.E. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr 2009, 89(4):1173-1179.
14. Muller M.J., Bosy-Westphal A., Kutzner D., Heller M. Metabolically active components of fat-free mass and resting energy expenditure in humans: recent lessons from imaging technologies. Obes Rev 2002, 3(2):113-122.
15. McMillan D.C., Watson W.S., Preston T., McArdle C.S. Lean body mass changes in cancer patients with weight loss. Clin Nutr 2000, 19(6):403-406.
16. Simons J.P., Schols A.M., Buurman W.A., Wouters E.F. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 1999, 97(2):215-223.
17. Pichard C., Kyle U.G. Body composition measurements during wasting diseases. Curr Opin Clin Nutr Metab Care 1998, 1(4):357-361.
18. Plank L.D. Dual-energy X-ray absorptiometry and body composition. Curr Opin Clin Nutr Metab Care 2005, 8(3):305-309.
19. Shen W., Punyanitya M., Wang Z., et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 2004, 97(6):2333-2338.
20. Mourtzakis M., Prado C.M., Lieffers J.R., Reiman T., MacCargar L.J., Baracos V.E.A. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008, 33(5):997-1006.
21. Staal-van den Brekel A.J., Schols A.M., Dentener M.A., ten velde G.P., Buurman W.A., Wouters E.F. Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls. Thorax 1997, 52(4):338-341.
22. Ross P.J., Ashley S., Norton A., et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?. Br J Cancer 2004, 90(10):1905-1911.
23. Roubenoff R. Sarcopenia: effects on body composition and function. J Gerontol A Biol Sci Med Sci 2003, 58(11):1012-1017.
24. Berger M.J., Doherty T.J. Sarcopenia: prevalence, mechanisms, and functional consequences. Interdiscip Top Gerontol 2010, 37:94-114.
25. Lauretani F., Russo C.R., Bandinelli S., et al. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol 2003, 95(5):1851-1860.
26. Morley J.E. Sarcopenia: diagnosis and treatment. J Nutr Health Aging 2008, 12(7):452-456.
27. Fearon K., Evans W.J., Anker S.D. Myopenia-a new universal term for muscle wasting. J Cachexia Sarcopenia Muscle 2011, 2(1):1-3.
28. Baumgartner R.N., Koehler K.M., Gallagher D., et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998, 147(8):755-763.
29. Roubenoff R. Sarcopenia and its implications for the elderly. Eur J Clin Nutr 2000, 54(Suppl 3):S40-S47.
30. Prado C.M., Lieffers J.R., McCargar L.J., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008, 9(7):629-635.
31. Schutz Y., Kyle U.U., Pichard C. Fat-free mass index and fat mass index percentiles in Caucasians aged 18-98 y. Int J Obes Relat Metab Disord 2002, 26(7):953-960.
32. Evans W.J. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr 2010, 91(4):1123S-1127S.
33. Rolland Y., Abellan Van Kan G., Gillette Guyonnet S., Vellas B. Cachexia versus sarcopenia. Curr Opin Clin Nutr Metab Care 2011, 14(1):15-21.
34. Manini T.M., Clark B.C. Dynapenia and aging: an update. J Gerontol A Biol Sci Med Sci 2011.
35. Irigaray P., Newby J.A., Lacomme S., Belpomme D. Overweight/obesity and cancer genesis: more than a biological link. Biomed Pharmacother 2007, 61(10):665-678.
36. Baracos V.E., Reiman T., Mourtzakis M., Gioulbasanis I., Antoun S. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010, 91(4):1133S-1137S.
37. Roubenoff R. Sarcopenic obesity: the confluence of two epidemics. Obes Res 2004, 12(6):887-888.
38. Fredrix E.W., Saris W.H., Soeters P.B., et al. Estimation of body composition by bioelectrical impedance in cancer patients. Eur J Clin Nutr 1990, 44(10):749-752.
39. Houtkooper L.B., Lohman T.G., Going S.B., Howell W.H. Why bioelectrical impedance analysis should be used for estimating adiposity. Am J Clin Nutr 1996, 64(3 Suppl):436S-448S.
40. Gupta D., Lis C.G., Dahlk S.L., Vashi P.G., Grutsch J.F., Lammersfeld C.A. Bioelectrical impedance phase angle as a prognostic indicator in advanced pancreatic cancer. Br J Nutr 2004, 92(6):957-962.
41. Gupta D., Lammersfeld C.A., Vashi P.G., et al. Bioelectrical impedance phase angle in clinical practice: implications for prognosis in stage IIIB and IV non-small cell lung cancer. BMC Cancer 2009, 28:9-37.
42. Paiva S.I., Borges L.R., Halpern-Silveira D., Assunção M.C., Barros A.J., Gonzales M.C. Standardized phase angle from bioelectrical impedance analysis as prognostic factor for survival in patients with cancer. Support Care Cancer 2009.
43. Santarpia L., Marra M., Montagnese C., Alfonsi L., Pasanisi F., Contaldo F. Prognostic significance of bioelectrical impedance phase angle in advanced cancer: preliminary observations. Nutrition 2009, 25(9):930-931.
44. Davis M.P., Yavuzsen T., Khoshknabi D., et al. Bioelectrical impedance phase angle changes during hydration and prognosis in advanced cancer. Am J Hosp Palliat Care 2009, 26(3):180-187.
45. Reilly J.J., Workman P. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol 1993, 32(6):411-418.
46. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996, 14(9):2590-2611.
47. Grochow L.B., Baraldi C., Noe D. Is dose normalization to weight or body surface area useful in adults?. J Natl Cancer Inst 1990, 82(4):323-325.
48. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7(11):1748-1756.
49. Ratain M.J. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?. J Clin Oncol 1998, 16(7):2297-2298.
50. Morgan D.J., Bray K.M. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 1994, 26(4):292-307.
51. Gurney H.P., Ackland S., Gebski V., Farell G. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 1998, 16(7):2299-2304.
52. Dignam J.J., Polite B.N., Yothers G., et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 2006, 98(22):1647-1654.
53. Meyerhardt J.A., Tepper J.E., Niedzwiecki D., et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 2004, 22(4):648-657.
54. Antoun S., Baracos V.E., Birdsell L., Escudier B., Sawyer M.B. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010, 21(8):1594-1598.
55. Prado C.M., Baracos V.E., McCargar L.J., et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007, 13(11):3264-3268.
56. Prado C.M., Baracos V.E., McCargar L.J., et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009, 15(8):2920-2926.
57. Thibault R., Cano N., Pichard C. Quantification of lean tissue losses during cancer and HIV infection/AIDS. Curr Opin Clin Nutr Metab Care 2011, 14(3):261-267.